OncoMatch/Clinical Trials/NCT04999943

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

Is NCT04999943 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DC vaccine for myelodysplastic syndromes.

Phase 1RecruitingAffiliated Hospital to Academy of Military Medical SciencesNCT04999943Data as of May 2026

Treatment: DC vaccine — The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.

Check if I qualify

Extracted eligibility criteria

Cancer type

Myelodysplastic Syndrome

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Kidney function

normal function of kidney, serum creatinine ≤ 150 umol / L

Liver function

normal function of liver, serum bilirubin ≤ 35 umol / L

Cardiac function

normal function of heart

normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol / L; serum creatinine ≤ 150 umol / L

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify